We have today received confirmation that agreements between Vertex and NHS Wales and Vertex and NHS Northern Ireland have been finalised. The agreement is comparable to the NHS England one, announced on Thursday 20 June, and will provide access to modulator therapies for all existing and future eligible CF patients in Wales and Northern Ireland.
The National Institute for Health and Care Excellence (NICE) have today (20 June) given approval for the life changing cystic fibrosis (CF) modulator drugs – Kaftrio, Symkevi and Orkambi - to be made available on the NHS in England. This follows many years of campaigning by Cystic Fibrosis Trust and people right across the CF community.
Bowel Research UK have today released a special episode of their podcast, Can I Butt In? for CF Week, discussing the connection between cystic fibrosis and bowel conditions.
For 60 years we've worked together, sharing moments of frustration, despair and hope, overcoming challenges, and celebrating breakthroughs. Always learning and moving forward. This CF Week, we’re reflecting on how far we’ve come and looking to the future. Because we won’t stop until CF does.
Today, we’re going inside the lab to chat to CF researcher Professor Pietro Cicuta, who is based at the University of Cambridge. “I think CF still holds a lot of mysteries,” he tells us.
You can now find summaries of recently-published clinical trial results on our Trials Tracker. In this blog, we share more about how we’re making trial results more accessible and why it's important.
As the Trust marks its 60th anniversary year, Robyn, who has CF, will be celebrating her first birthday with an arts and crafts party with all her family. “My hope for my daughter’s future is that she goes out and takes the world by storm and shows everyone that she is more than her condition,” mum Laya tells us.
Professor Jane Davies, Paediatric Respiratory Medicine and Experimental Medicine at Imperial College London and an Honorary Consultant at the Royal Brompton Hospital has been awarded an OBE for services to people with cystic fibrosis.
